Philadelphia-based Mylan and India-based Biocon are teaming up to develop generic biotech drugs. "It makes sense that Mylan, which is an expert in making generic copies of traditional drugs, would partner with an outside firm that focuses on biotech. By the same token, cracking the market for generic biotechs in the developed world might also be tricky - so it makes sense that an Indian firm might want a U.S. partner," says the Wall Street Journal Health Blog. The post adds that the new partnership will have plenty of competition.
Cracking the Market
Jun 29, 2009